Contract Award with new client
Contract award with new UK biotech client for £102,000 running April to August 2025.
- Contract value £102,000
- Project duration April 2025 to August 2025
Select text to share a quote on X · sign in to keep highlights & notes in your PYC notes
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is delighted to announce a contract award with a new UK-based biotech company developing antibody drug conjugates (ADCs) based therapies targeting hard-to-treat cancers.
This new project will see the Company develop a Pharmacokinetic (PK) Pharmacodynamic (PD) model to inform optimal dosing for the client's upcoming First-in-Human trial. The project is valued at £102,000 and is projected to run from April 2025 until August 2025.
Dr Peter Sargent, CEO, commented:
"We are delighted to be awarded this contract. Not only is this contract with a brand new client, but is also in the area of ADCs; a hot new area of oncology treatments. This reflects the Company's strategy to diversify its client base, and expand its offering into new therapeutic modalities and areas of drug development."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.